These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27284161)

  • 1. BSR and BHPR guideline for the treatment of systemic sclerosis.
    Denton CP; Hughes M; Gak N; Vila J; Buch MH; Chakravarty K; Fligelstone K; Gompels LL; Griffiths B; Herrick AL; Pang J; Parker L; Redmond A; van Laar J; Warburton L; Ong VH;
    Rheumatology (Oxford); 2016 Oct; 55(10):1906-10. PubMed ID: 27284161
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.
    Pellar RE; Pope JE
    Semin Arthritis Rheum; 2017 Jun; 46(6):767-774. PubMed ID: 28088339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Pope J; Harding S; Khimdas S; Bonner A; ; Baron M
    J Rheumatol; 2012 Mar; 39(3):524-31. PubMed ID: 22247347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).
    Harding S; Khimdas S; Bonner A; Baron M; Pope J;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S38-43. PubMed ID: 22691207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.
    Strange G; Nash P
    Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New ACR EULAR guidelines for systemic sclerosis classification.
    Johnson SR
    Curr Rheumatol Rep; 2015 May; 17(5):32. PubMed ID: 25874345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Systemic Sclerosis: A Practical Approach.
    Lee JJ; Pope JE
    Drugs; 2016 Feb; 76(2):203-13. PubMed ID: 26659258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rheumatology: Progress in Diagnosis and Treatments. Topics: IV. Collagen Diseases Except for Rheumatoid Arthritis and Hot Topics: 3. Systemic sclerosis (Scleroderma)].
    Yasuoka H
    Nihon Naika Gakkai Zasshi; 2014 Oct; 103(10):2481-6. PubMed ID: 27514197
    [No Abstract]   [Full Text] [Related]  

  • 11. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of systemic sclerosis.
    Pope JE
    Rheum Dis Clin North Am; 1996 Nov; 22(4):893-907. PubMed ID: 8923602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension.
    Opitz C; Klein-Weigel PF; Riemekasten G
    Vasa; 2011 Jan; 40(1):20-30. PubMed ID: 21283970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
    Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.
    Shuck JW; Oetgen WJ; Tesar JT
    Am J Med; 1985 Feb; 78(2):221-7. PubMed ID: 3970048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABC of rheumatology. Raynaud's phenomenon, scleroderma, and overlap syndromes.
    Isenberg DA; Black C
    BMJ; 1995 Mar; 310(6982):795-8. PubMed ID: 7711588
    [No Abstract]   [Full Text] [Related]  

  • 18. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
    Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
    Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
    Hummers LK; Wigley FM
    Rheum Dis Clin North Am; 2003 May; 29(2):293-313. PubMed ID: 12841296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of systemic sclerosis.
    Pope J
    Curr Opin Rheumatol; 1993 Nov; 5(6):792-801. PubMed ID: 7509616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.